Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiLLI: Thromboprophylaxis in Lower Limb Immobilisation
NCT06370273Phase 3Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Nov 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban and apixaban in thrombosis (5 arms), sponsored by Queen Mary University of London. Primary endpoint: Composite of net clinical benefit at 90 days. Started Nov 2024; status: recruiting.
02
Drugs
rivaroxabanapixaban
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT06370273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370273.